NLRP3 and cryopyrin-associated periodic syndrome: Interestingly, MCC950/CRID3 and related diarylsulfonylurea compounds may be substantially less effective in inhibiting CAPS‐related NLRP3 mutants because in vivo MCC950/CRID3 concentrations that potently inhibited NLRP3‐driven inflammation in wildtype mice were shown to be ineffective in two in vivo mouse models of CAPS disease.119